Immunotherapy for advanced or limited-spread lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether starting immunotherapy can help people with newly diagnosed advanced or limited-spread non-small cell lung cancer that cannot be fully cured with standard local treatments. It may offer a new treatment approach when surgery or definitive chemoradiation isn’t a good option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have newly diagnosed non-small cell lung cancer (NSCLC) confirmed by a biopsy or fluid test
- Your cancer stage is III to IVA, or it has only a limited number of spread sites (oligometastatic) based on full scans
- Your overall health allows you to do daily activities with little help (ECOG 0 to 2)
- Your doctor expects you may live at least about 3 more months
- You can sign a consent form and understand the trial steps
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (tislelizumab) with standard chemotherapy (and sometimes radiation) for people with small cell lung cancer that has spread to only a few spots in the body. The goal is to see if adding immunotherapy helps control the cancer better than chemotherapy alone.
This trial looks at adding two immunotherapy drugs to radiation and chemotherapy for people with stage 3 lung cancer that cannot be removed by surgery. It compares giving immunotherapy during radiation versus giving it after radiation, to see which way may help control the cancer better.
This trial tests a new approach for people with certain advanced non-small cell lung cancer (NSCLC) that has spread to lymph nodes in the chest but might still be removed. It combines a short course of high-precision radiation, immunotherapy (sintilimab), and standard chemotherapy before surgery to see if it can improve outcomes.
This trial tests a new approach for people with stage III lung cancer that cannot be removed with surgery. You would receive immunotherapy (to help your immune system fight cancer) plus chemotherapy first, then standard chemo-radiation, and finally more immunotherapy. The goal is to see if this sequence works better than standard treatment.
This trial tests combining immunotherapy with a shorter course of chemoradiation for locally advanced non-small cell lung cancer that hasn't spread. It aims to see if this approach is more effective and tolerable than standard treatment.
This trial tests a new combination of immunotherapy and chemotherapy before and after standard chemoradiation for patients with stage III lung cancer that cannot be surgically removed. The goal is to see if this approach improves outcomes compared to chemoradiation alone.
Hear when a new Carcinoma, Non-Small-Cell Lung trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.